By: Dr. Shane Kurth, D.C., BCN
Co-Owner, Radiant Results
Updated September 2026

This guide covers the full spectrum of non-hormonal menopause support options — from FDA-approved prescription medications to lifestyle interventions, mind-body therapies, and adjunct modalities including red light therapy. It is written to help women understand what the evidence actually supports for each category, including honest acknowledgment of where evidence is strong, where it is emerging, and where claims outrun the data. It does not argue against hormone therapy; where HRT is appropriate, it remains the first-line standard of care.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Non-hormonal menopause management involves significant individual variability. Consult a qualified healthcare provider — OB-GYN, internist, or menopause specialist — before beginning or changing any treatment protocol.

Non-Hormonal Menopause Treatment Options: A Clinician’s Evidence Guide

Non-hormonal menopause treatment options now include three FDA-approved prescription medications, several guideline-endorsed behavioral interventions, and a growing category of adjunct modalities. The three approved non-hormonal medications for vasomotor symptoms are low-dose paroxetine (Brisdelle, FDA-approved 2013), fezolinetant (Veozah, FDA-approved May 2023), and elinzanetant (Lynkuet, FDA-approved October 2025). Cognitive-behavioral therapy and clinical hypnosis carry the Menopause Society’s highest evidence rating — Level I — alongside resistance training and weight loss as guideline-supported lifestyle interventions. The evidence landscape for women pursuing menopause without hormones is considerably richer than it was a decade ago, though the strength of that evidence varies by option and symptom target.

Key Takeaways

• HRT remains first-line. Per the Menopause Society, hormone therapy is the most effective treatment for vasomotor symptoms and should be considered in menopausal women within ten years of their final menstrual period. Non-hormonal options are a legitimate, increasingly evidence-backed alternative for women who cannot or choose not to use HRT — not a superior replacement.
• Three FDA-approved non-hormonal Rx options now exist for moderate-to-severe vasomotor symptoms: Brisdelle (paroxetine 7.5mg, 2013), Veozah (fezolinetant, May 2023), and Lynkuet (elinzanetant, October 2025) — all mechanism-specific, none containing estrogen.
• Resistance training and CBT are NAMS-recommended at Level I for non-hormonal hot flash management — the same evidence tier as prescription SSRIs/SNRIs for this indication.
• Supplements and botanical remedies are not recommended by the NAMS 2023 Nonhormone Therapy Position Statement for vasomotor symptom control. Insufficient clinical evidence is not the same as evidence of harm, but it does mean these options lack guideline endorsement.
• Red light therapy does not treat hot flashes or replace hormones. It carries emerging-to-moderate evidence for several menopause-adjacent symptoms — joint pain, inflammation, skin collagen changes, and muscle recovery — that may complement a broader non-hormonal strategy.

Why Non-Hormonal Menopause Support Is a Legitimate Clinical Path

Hormone therapy is the first-line standard of care for menopausal vasomotor symptoms, and this guide does not argue otherwise. The Menopause Society is explicit: hormone therapy is the most effective treatment for hot flashes and should be considered in women within ten years of their final menstrual period who have no contraindications.

Non-hormonal options are the medically appropriate primary pathway for a specific population: women with a personal history of hormone-sensitive cancers such as breast or endometrial cancer, a history of blood clots or deep vein thrombosis, or certain cardiovascular conditions — as well as women who, after an informed discussion with their provider, choose to avoid systemic hormones. For these women, the non-hormonal options below are not a compromise. They are the appropriate standard of care.

FDA-Approved Non-Hormonal Medications

Brisdelle (Low-Dose Paroxetine 7.5mg)

Brisdelle was FDA-approved in 2013 and remains the only SSRI with a specific approval for menopausal hot flashes. Its mechanism involves serotonin reuptake inhibition in the hypothalamus, which modulates thermoregulatory signaling. This is a different pathway from the NK3R mechanism driving the newer agents. The 7.5mg dose is lower than standard antidepressant dosing, and Brisdelle is not approved or indicated for depression at this strength.

One clinically important interaction: women taking tamoxifen for breast cancer should discuss paroxetine with their oncologist before use. Paroxetine inhibits CYP2D6 and may reduce tamoxifen’s therapeutic effectiveness — this is a mandatory prescriber conversation.

Veozah (Fezolinetant) — FDA-Approved May 2023

Fezolinetant represents a mechanistically distinct approach to non-hormonal hot flash treatment. Estrogen plays a regulatory role for the neuropeptide Neurokinin B (NKB), which activates neurokinin-3 receptors (NK3R) on KNDy neurons in the hypothalamus — neurons central to thermoregulation. As estrogen falls after menopause, NKB signaling becomes dysregulated, and this dysregulation is the proximate driver of hot flashes and night sweats. Fezolinetant blocks the NK3 receptor directly, quieting this dysregulated signal without introducing estrogen, as documented in a 2025 review in the Annals of Medicine and Surgery (PMC12401328).

The SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 Phase 3 trials demonstrated significant reductions in vasomotor symptom frequency and severity. The most common adverse effects were headache and fatigue. Importantly, in December 2024 the FDA added a Boxed Warning to fezolinetant for rare but serious liver injury; prescribing information now requires liver function monitoring monthly for the first two months, then at months 3, 6, and 9. Women with pre-existing liver conditions or cirrhosis should not take fezolinetant. This is a mandatory prescriber discussion.

Lynkuet (Elinzanetant) — FDA-Approved October 2025

Elinzanetant is the most recent FDA-approved non-hormonal menopause medication in this class and the first dual neurokinin-targeted therapy approved for this indication — blocking both NK1 and NK3 receptors simultaneously. The FDA approved Lynkuet (Bayer) on October 24, 2025 for moderate-to-severe hot flashes due to menopause. Veozah targets NK3 alone. Lynkuet’s additional NK1 blockade modulates substance P, a neuropeptide involved in pain and sleep regulation — which is the structural basis for its observed effects on sleep quality.

The OASIS 1, 2, and 3 Phase 3 trials showed significant reductions in vasomotor symptom frequency and severity with a favorable safety profile. The OASIS program also captured improvements in sleep disturbance and menopause-related quality of life (Pinkerton JV, Simon JA, Joffe H, et al. JAMA. 2024;332(16):1343–1354). As with fezolinetant, hepatic transaminase elevations were observed in trials, so baseline liver evaluation is performed before initiating treatment; Lynkuet is also contraindicated in pregnancy. Neither Veozah nor Lynkuet has been compared head-to-head in a published trial. The choice between them is a prescriber-level decision based on individual symptom profile, particularly whether sleep disruption is a prominent complaint.

Off-Label Prescription Options

SSRIs and SNRIs — particularly venlafaxine and escitalopram — and gabapentin carry NAMS 2023 Level I recommendations for non-hormonal vasomotor symptom management despite lacking FDA approval specifically for this indication, per the 2023 Menopause Society position statement (PubMed 37252752). “Guideline-endorsed” and “FDA-approved” are distinct designations. Both matter clinically, and neither replaces a conversation with a licensed prescriber who can assess individual fit.

All prescription options in this section require evaluation and a prescription from a licensed clinician. This section is informational only — it is not a prescribing guide.

Lifestyle as Medicine: Why Resistance Training Leads the Evidence Base

Lifestyle interventions are frequently mentioned in menopause guides and just as frequently underspecified. The evidence base is not uniform across exercise types, and calibrating what the research actually supports matters for informed decisions.

What NAMS 2023 Does and Does Not Recommend

The NAMS 2023 Nonhormone Therapy Position Statement recommends weight loss (Levels II–III) as a non-hormonal option for vasomotor symptoms, noting that weight loss may decrease the number and severity of hot flashes — especially early in the menopausal transition. Exercise as a broad category does not carry a specific NAMS recommendation for VMS control. The panel’s evidence review did not reach recommendation threshold for exercise as a non-hormonal hot flash treatment specifically. This distinction is important and is often glossed over in general wellness content.

What exercise does have — and what menopause-related evidence strongly supports — is a robust evidence base for the broader cluster of changes that drive quality of life: bone density, sarcopenia, metabolic health, and mood.

Resistance Training and Bone Density

Estrogen withdrawal accelerates bone loss, making postmenopausal osteoporosis one of the most clinically significant non-vasomotor consequences of menopause. A 2025 meta-analysis of 17 randomized controlled trials involving 690 subjects found that resistance training significantly improves bone mineral density at the lumbar spine (SMD = 0.88), femoral neck (SMD = 0.89), and total hip (SMD = 0.30), published in the Journal of Orthopaedic Surgery and Research (PubMed 40420105). A complementary network meta-analysis in Frontiers in Physiology (PMC9941565) found that moderate-intensity resistance training three days per week can be preferred clinically to improve bone mineral density in postmenopausal women.

These are not trivial effect sizes. Resistance training’s evidence for postmenopausal bone health is among the strongest available for any non-pharmacological intervention.

Resistance Training and Vasomotor Symptoms

A 2024 meta-analysis in the Journal of Bodywork and Movement Therapies (PubMed 38876649) found that vasomotor symptoms decreased significantly in resistance training groups compared to controls following intervention (SMD = −1.31, 95% CI: −1.85 to −0.77, p = 0.002). This is a meaningful signal. However, the meta-analysis pooled only five studies with small sample sizes — a limitation the NAMS 2023 panel weighted heavily when it did not reach a formal recommendation. The evidence is promising and warrants clinical attention, but it has not yet cleared the Level I bar that CBT and pharmaceutical options have.

Sarcopenia and Muscle Preservation

Menopause accelerates sarcopenic muscle loss — a process that compounds with natural age-related decline in muscle mass. Resistance training is the primary non-pharmacological countermeasure with an established evidence base. Women using resistance training as a core pillar of their non-hormonal strategy may find red light therapy for muscle recovery a useful adjunct for managing post-exercise soreness and supporting training consistency.

A certified fitness professional can provide individualized programming. Compound movements — squats, deadlifts, rows — with progressive load, two to three sessions per week, are a reasonable general framework that any trainer or physical therapist can adapt to individual capacity and injury history.

Mind-Body Therapies: CBT and Clinical Hypnosis in the NAMS Guidelines

Mind-body therapies occupy an underappreciated position in the non-hormonal evidence base. The 2023 NAMS Nonhormone Therapy Position Statement was developed by a panel of clinician-researchers with special expertise in nonhormone medical therapy, behavioral therapy, herbal therapy, and lifestyle management for vasomotor symptoms — and their conclusions about two specific mind-body modalities carry more clinical weight than most readers expect.

Cognitive-Behavioral Therapy

CBT carries a NAMS 2023 Level I recommendation for VMS management — the highest evidence tier in the statement, equivalent to FDA-approved Rx options for this indication. The evidence base includes data from multiple randomized controlled trials, notably the MENOS 1 and MENOS 2 studies. CBT for menopause is a structured behavioral intervention — typically four to eight weekly sessions — combining patient education, motivational interviewing, and relaxation strategies.

Its mechanism is cognitive rather than physiological. CBT helps women perceive hot flashes as less of a problem by changing the catastrophic appraisal of symptoms. The hot flashes themselves may not become less frequent, but their perceived severity and interference with sleep, concentration, and daily function decrease measurably. Women who enter CBT expecting a physiological reduction in hot flash frequency will find that framing clarifying — the goal is functional improvement, and the evidence demonstrates it.

Clinical Hypnosis

Clinical hypnosis guides individuals into a deeply relaxed state of focused attention and is used in clinical settings to manage pain and anxiety. NAMS 2023 recommends clinical hypnosis at Level I — a finding that surprises most patients and many clinicians unfamiliar with the evidence. Research shows clinical hypnosis can reduce both the number and severity of hot flashes. This recommendation applies to clinical hypnosis delivered by a trained practitioner, not self-hypnosis audio products — that distinction matters for outcome expectations.

What NAMS Does Not Recommend for VMS

The 2023 position statement does not recommend mindfulness-based intervention, yoga, paced respiration, or relaxation techniques specifically for vasomotor symptom control. Evidence for hot flash reduction from these practices did not meet the panel’s threshold for a recommendation. They may support stress regulation, sleep quality, and general wellbeing — but their value for VMS control is unestablished at a guideline level.

Stellate Ganglion Block

The NAMS 2023 statement recommends stellate ganglion block (SGB) at Levels II–III. SGB is a nerve block procedure targeting the stellate ganglion in the neck, with emerging evidence for hot flash reduction in select candidates. SGB is a specialist procedure requiring evaluation by a pain management physician or anesthesiologist. Women interested in this option should raise it with their OB-GYN for a referral assessment rather than seeking it directly.

The take-home for this category: CBT and clinical hypnosis are not soft wellness alternatives — they share an evidence tier with prescription medications for this indication and belong in any complete non-hormonal evaluation.

Supplements and Botanicals: Where the Evidence Falls Short

The supplement category is where honest calibration matters most, because the marketing landscape is furthest removed from the clinical evidence. The NAMS 2023 Nonhormone Therapy Position Statement does not recommend supplements or herbal remedies for vasomotor symptom control (Levels I–II) (PubMed 37252752). Understanding what that designation means — and what it does not — is essential context.

“Not recommended” means the panel reviewed available evidence and found it insufficient to support a population-level recommendation. This is not the same as evidence of harm. Some women report subjective improvement; the issue is that randomized controlled trial evidence is inconsistent and often insufficiently powered to distinguish real effect from placebo response in this symptom category.

Black Cohosh

Black cohosh is the most extensively studied botanical for menopause. Some clinical trials have documented modest hot flash reduction; others have found no benefit over placebo. Black cohosh does not appear to have estrogenic activity — a point of interest for women with hormone-sensitive cancer histories, though this does not resolve the efficacy question. Rare hepatotoxicity reports exist at high doses. Women should discuss dose and duration with a pharmacist or physician before starting.

Phytoestrogens (Soy Isoflavones, Red Clover)

Phytoestrogens are plant compounds with weak estrogen-like receptor activity. Evidence for hot flash reduction is inconsistent across trials. Women with hormone-sensitive cancers or those on hormone-modulating therapies should discuss phytoestrogen intake with their oncologist before use — the estrogen-receptor interaction, even if weak, warrants that conversation.

Supplements Without Meaningful VMS Evidence

Evening primrose oil, vitamin E, and flaxseed lack meaningful clinical evidence for vasomotor symptom control. Some may have general health benefits in other contexts, but they should not be selected specifically for hot flash treatment based on current literature.

Sleep-Focused Supplements

Melatonin and magnesium are not VMS treatments but may address the sleep disruption that frequently accompanies menopause as a distinct symptom. They target a downstream consequence, not the thermoregulatory mechanism driving hot flashes. A provider can clarify which symptoms are driving quality-of-life impact and which interventions are targeted to each.

Before starting any botanical or supplement product, a conversation with a pharmacist and OB-GYN is warranted. Drug-herb interactions and potential effects on hormone-sensitive conditions are real clinical considerations that online product labeling does not address.

Where Red Light Therapy Fits in a Non-Hormonal Strategy

This section requires careful framing — because both overclaiming and ignoring this modality would disserve the reader.

The Honest Limitation First

Red light therapy — more precisely, photobiomodulation (PBM) — does not treat vasomotor symptoms. It does not reduce hot flash frequency or severity, and it does not replace hormones. It is not an alternative to Brisdelle, Veozah, or Lynkuet. Any source suggesting otherwise should be read with significant skepticism. This limitation is stated first because it is the trust signal — a reader who has encountered inflated claims elsewhere will recognize calibrated honesty when they find it.

How Photobiomodulation Works

Photobiomodulation delivers specific wavelengths of red (~630–660nm) and near-infrared (~810–850nm) light to tissue. These wavelengths are absorbed by cytochrome c oxidase in the mitochondrial electron transport chain, supporting ATP production and modulating downstream inflammatory pathways, as described in Hamblin’s 2017 mechanisms review (PMC5523874). Red light penetrates approximately 8–10mm into tissue. Near-infrared penetrates 2–5cm at the 810–850nm range. Therapeutic effects depend on this depth-matched, wavelength-specific delivery reaching target tissue.

Where RLT Has Relevant Evidence

Joint pain and inflammation: Menopause-associated joint pain — sometimes called menopausal arthralgia — is among the most common and undertreated non-vasomotor menopause symptoms. A literature review of 11 randomized controlled trials found that photobiomodulation positively influenced chronic pain in five studies; in two others, patient inflammation improved markedly. The authors concluded photobiomodulation has beneficial effects on chronic pain and inflammation, while noting more research is needed (PMC10094541). For women in whom joint pain is a primary quality-of-life driver, this is where the clearest RLT evidence applies. Our red light therapy for joint pain resource covers that application specifically.

Skin and collagen: Menopause-related collagen loss is a documented consequence of estrogen withdrawal, with dermatology literature noting accelerated collagen degradation in the early postmenopausal years. Avci et al. document photobiomodulation’s support for collagen synthesis and fibroblast activity in dermatologic applications, in a 2013 study in Seminars in Cutaneous Medicine and Surgery (PMC4126803). Our red light therapy for skin rejuvenation resource covers that evidence in depth.

Muscle recovery: Photobiomodulation’s ability to reduce inflammation and support muscle recovery is well documented in sports medicine and rehabilitation contexts — working through enhanced cellular energy production (ATP), reduced oxidative stress, and improved local circulation (PMC5523874). For women building resistance training into their non-hormonal strategy, RLT may support recovery between sessions and help sustain training consistency. Bone and sarcopenia benefits of resistance training accrue over 48 or more weeks of consistent practice; recovery support matters over that timeline.

Sleep: Early evidence suggests near-infrared light exposure may influence circadian regulation and melatonin-related pathways. Research specifically in menopausal women is limited and the mechanism is not well established in this population. This remains an area of interest rather than established practice.

Radiant Results Clinical Context

The Dahlia Full Body Medical Grade Light Therapy Bed delivers red (~630–660nm) and near-infrared (~810–850nm) wavelengths simultaneously across full-body surface area in 15-minute sessions. The design includes a facial protection pad that preserves facial skin appearance during full-body sessions. For women tracking body composition changes over a non-hormonal protocol, the Styku 3D body scanner provides objective progress measurement across serial sessions.

Safety Considerations for Red Light Therapy

Photobiomodulation is considered safe for most healthy adults, but the following situations require a provider conversation before use:

• Photosensitizing medications: Certain prescription and over-the-counter medications — including some antibiotics, diuretics, and retinoids — increase skin sensitivity to light. Disclose all medications to your provider before beginning RLT.
• Pregnancy: Safety data for photobiomodulation during pregnancy are insufficient to support routine use. Women who are pregnant or may be pregnant should not use RLT without explicit guidance from their OB-GYN.
• Active cancer or photosensitive conditions: Women with active malignancy or photosensitive skin conditions should obtain oncologist or dermatologist clearance before beginning any light therapy.
• Eye protection: Direct exposure of the eyes to therapeutic-level red and near-infrared light requires appropriate protective eyewear. Clinical devices should be operated by trained staff.

For general FDA guidance on light-emitting devices, the FDA’s overview of light therapy devices provides regulatory context. Radiant Results staff can answer session-specific questions and facilitate provider communication where needed.

Honest Evidence Summary

Research on photobiomodulation applied specifically to perimenopausal or menopausal women as a defined population is limited. Most studies have been conducted in mixed or general chronic pain and inflammation populations. The strongest evidence applies to individual symptom categories — joint pain, inflammation, skin, muscle recovery — rather than to menopause as a condition. The appropriate position for RLT in a non-hormonal strategy is as a cellular-level adjunct with evidence in several relevant symptom categories: one layer of a multi-modal approach, considered alongside guideline-endorsed options.

Radiant Results — Uptown Charlotte. Women exploring medical-grade red light therapy as part of a non-hormonal support strategy can get started with the $79 New Patient Special, which includes a full-body photobiomodulation session and a Styku 3D body composition scan. Claim the $79 New Patient Special →

19824 W Catawba Ave, Suite G, Cornelius, NC 28031

Matching Options to Symptoms: A Decision Framework

The table below organizes non-hormonal options by symptom target, evidence tier, and key clinical considerations. It is not a prescribing guide — it is a structured starting point for a conversation with a qualified provider.

This framework is a starting point, not a prescription. The most productive use of this table is as a pre-appointment reference — bringing specific questions about mechanism, evidence tier, and individual contraindications to a clinician who can assess fit within the context of a complete medical history.

Questions to Bring to Your OB-GYN

Arriving at a provider appointment with specific, informed questions improves the quality of the conversation and the likelihood of leaving with a clear, individualized plan.

On prescription options:

• “Am I a candidate for fezolinetant (Veozah) or elinzanetant (Lynkuet), and what monitoring would be involved?”
• “Would an off-label SSRI or SNRI for hot flashes be appropriate given my other medications?”
• “What’s the prescribing consideration for Brisdelle if I’m currently on or might need tamoxifen?”

On lifestyle and behavioral options:

• “Can you refer me to a therapist trained in CBT for menopause symptoms?”
• “How does my current bone density status inform how aggressively I should prioritize resistance training?”
• “Would weight loss realistically affect my vasomotor symptom frequency at this stage?”

On adjunct modalities:

• “Are there any contraindications I should know about for red light therapy given my health history or medications?”
• “How should I think about supplement interactions with any medications or conditions I have?”

On the overall strategy:

• “Should I be using a single approach or combining options from different categories?”
• “What would a reasonable timeline look like before we evaluate whether an intervention is working?”
• “What symptoms should prompt me to come back sooner rather than waiting for a scheduled follow-up?”

These questions reflect the level of specificity that leads to individualized answers rather than general reassurances.

Frequently Asked Questions

What is the most effective non-hormonal treatment for menopause hot flashes?

No single non-hormonal treatment matches HRT for hot flash control — that distinction is important to state clearly. Among non-hormonal options, the FDA-approved NK3R antagonists (Veozah and Lynkuet) have shown the most consistent hot flash reduction in Phase 3 RCTs. CBT and clinical hypnosis carry NAMS 2023 Level I recommendations — the same evidence tier as prescription SSRIs/SNRIs — with demonstrated reductions in perceived severity and daily impact. The most effective approach depends on medical history, other medications, symptom profile, and personal preferences. That determination requires a provider assessment.

What are the three FDA-approved non-hormonal menopause medications?

The three FDA-approved non-hormonal medications for moderate-to-severe vasomotor symptoms are: (1) Brisdelle (low-dose paroxetine 7.5mg), an SSRI approved in 2013; (2) Veozah (fezolinetant), a neurokinin-3 receptor antagonist approved in May 2023; and (3) Lynkuet (elinzanetant), a dual NK1 and NK3 receptor antagonist approved in October 2025. All three require a prescription. Several others — venlafaxine, escitalopram, and gabapentin — carry NAMS Level I recommendations for VMS but are not FDA-approved specifically for this indication.

Is red light therapy effective for menopause symptoms?

Red light therapy (photobiomodulation) does not treat vasomotor symptoms — it will not reduce hot flash frequency or night sweats, and does not replace any hormonal effect. It does carry emerging-to-moderate evidence for several symptoms that frequently accompany menopause: joint pain and inflammation, skin collagen changes, and muscle recovery support. A literature review of 11 RCTs found photobiomodulation has beneficial effects on chronic pain and inflammation, though reviewers noted more research is needed. Studies specifically in menopausal women as a defined population are limited. RLT’s appropriate role is as one layer of a multi-modal non-hormonal strategy — not a standalone menopause treatment.

Does resistance training reduce menopause hot flashes?

The evidence is promising but not definitive. A 2024 meta-analysis in the Journal of Bodywork and Movement Therapies found a statistically significant reduction in vasomotor symptoms in resistance training groups compared to controls (SMD = −1.31, p = 0.002). However, only five small studies were pooled, and the NAMS 2023 panel did not reach a formal recommendation for exercise as a VMS intervention. Resistance training has a much stronger evidence base for the non-vasomotor consequences of menopause — bone density, sarcopenia, metabolic health, and mood. Most clinicians consider it a foundational lifestyle component of any non-hormonal strategy, with the honest caveat that its hot flash benefit is not yet established at a guideline level.

What is the difference between Veozah and Lynkuet for menopause?

Both Veozah (fezolinetant) and Lynkuet (elinzanetant) modulate KNDy neurons in the hypothalamus that drive the temperature dysregulation behind hot flashes. The key difference is receptor specificity: Veozah blocks only the NK3 receptor, while Lynkuet blocks both NK1 and NK3 receptors simultaneously. NK1 receptor involvement is relevant to substance P signaling, which affects pain and sleep regulation — the OASIS Phase 3 trials for Lynkuet documented improvements in sleep disturbance alongside vasomotor symptom reduction. No head-to-head comparison trials have been published. The choice between them is a prescriber-level decision based on individual symptom priorities.

Where can Charlotte women access medical-grade red light therapy for menopause support?

Radiant Results in Uptown Charlotte offers the Dahlia Full Body Medical Grade Light Therapy Bed, delivering red (~630–660nm) and near-infrared (~810–850nm) wavelengths in 15-minute full-body sessions. For women incorporating RLT as an adjunct in a non-hormonal menopause strategy, the $79 New Patient Special includes a full-body photobiomodulation session and a Styku 3D body composition scan.

Sources

1. The North American Menopause Society. “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society.” Menopause. 2023;30(6):573–590. PMID: 37252752.
2. U.S. Food and Drug Administration / Bayer. Lynkuet (elinzanetant) FDA approval, October 24, 2025 — first dual NK1/NK3 receptor antagonist for moderate-to-severe vasomotor symptoms due to menopause.
3. Pinkerton JV, Simon JA, Joffe H, et al. “Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials.” JAMA. 2024;332(16):1343–1354. DOI: 10.1001/jama.2024.14618. (OASIS efficacy and sleep outcomes.)
4. Fezolinetant (Veozah) mechanism review. Annals of Medicine and Surgery. 2025. PMC12401328.
5. U.S. FDA. Boxed Warning added to fezolinetant (Veozah) for rare serious liver injury, Drug Safety Communication, December 16, 2024.
6. Resistance training and bone mineral density: systematic review and meta-analysis (17 RCTs, 690 subjects). Journal of Orthopaedic Surgery and Research. 2025. PubMed 40420105.
7. Resistance training and bone mineral density: network meta-analysis. Frontiers in Physiology. PMC9941565.
8. Resistance training and vasomotor symptoms: meta-analysis. Journal of Bodywork and Movement Therapies. 2024. PubMed 38876649.
9. Photobiomodulation for chronic pain and inflammation: literature review of 11 RCTs. PMC10094541.
10. Hamblin MR. “Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation.” AIMS Biophysics. 2017;4(3):337–361. PMID: 28748217. PMC5523874.
11. Avci P, et al. “Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.” Seminars in Cutaneous Medicine and Surgery. 2013;32(1):41–52. PMC4126803.
12. FDA — Light Therapy Devices. https://www.fda.gov/medical-devices/home-use-devices/light-therapy-devices